Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Applied Genetic Technologies Corp    AGTC

APPLIED GENETIC TECHNOLOGIES CORP (AGTC)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/15/2018 06/18/2018 06/19/2018 06/20/2018 06/21/2018 Date
4.3(c) 4.4(c) 4.35(c) 4.55(c) 4.5492 Last
97 163 64 305 84 807 97 709 2 290 Volume
-1.15% +2.33% -1.14% +4.60% -0.02% Change
More quotes
Financials (USD)
Sales 2018 26,2 M
EBIT 2018 -20,5 M
Net income 2018 -18,1 M
Debt 2018 -
Yield 2018 -
Sales 2019 26,6 M
EBIT 2019 -40,3 M
Net income 2019 -40,2 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 3,00x
Capi. / Sales2019 2,96x
Capitalization 78,8 M
More Financials
Company
Applied Genetic Technologies Corp. is a clinical-stage biotechnology company, which engages in the development of gene therapy products designed to transform the lives of patients with severe diseases in ophthalmology.Its product candidates are designed to treat X-linked retinoschisis,... 
More about the company
Surperformance© ratings of Applied Genetic Technologi
Trading Rating : Investor Rating :
More Ratings
Latest news on APPLIED GENETIC TECHNOLOGI
06/14APPLIED GENETIC TECHNOLOGIES : AGTC Announces Expansion of Clinical and Regulato..
AQ
06/07APPLIED GENETIC TECHNOLOGIES : Patent Issued for Promoters, Expression Cassettes..
AQ
05/31APPLIED GENETIC TECHNOLOGIES : U.S. Patents Awarded to Inventors in North Caroli..
AQ
05/09APPLIED GENETIC TECHNOLOGIES CORPORA : (AGTC) Analysts See $-0.25 EPS
AQ
05/09APPLIED GENETIC TECHNOLOGIES : Fiscal 3Q Earnings Snapshot
AQ
05/08APPLIED GENETIC TECHNOLOGIES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL..
AQ
05/08AGTC Announces Financial Results and Business Update for the Quarter Ended Ma..
GL
05/08APPLIED GENETIC TECHNOLOGIES CORP : Results of Operations and Financial Conditio..
AQ
04/30AGTC to Host Third Quarter Financial Results Conference Call and Webcast on M..
GL
04/18AGTC Doses First Patient in Phase 1/2 Clinical Study of Gene Therapy for the ..
GL
More news
Sector news : Bio Therapeutic Drugs
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
06/20Roche to Buy Rest of Cancer Firm -- WSJ
DJ
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/19Roche to Pay $2.4 Billion for Full Control of Foundation Medicine -- 2nd Upda..
DJ
More sector news : Bio Therapeutic Drugs
Latest Tweets
06/20William Sullivan, 45, pleaded guilty in Dauphin County Court to stealing $5,7.. 
06/20Applied Genetic Technologies Corp $AGTC Given Average Rating of “Buy” by Brok.. 
06/20William Sullivan, the former owner of Net Pay Solutions, pleaded guilty Tuesd.. 
06/16$6.87 Million in Sales Expected for Applied Genetic Technologies Corp $AGTC T.. 
06/11Want the latest analyst ratings on $TEGP $AGTC $SHBI $ALDX $MSLI? Get Them De.. 
More tweets
Qtime:71
News from SeekingAlpha
06/04MEIRAGTX IPO : Hedge Fund Managers Are Leading The Company 
06/01MeiraGTx Files To Raise $75 Million In IPO 
05/30Applied Genetic Tech files for $125M mixed shelf offering 
05/18MeiraGTx Aims For $86 Million U.S. IPO 
05/11Applied Genetic Technologies' (AGTC) CEO Sue Washer on Q3 2018 Results - Earn.. 
Chart APPLIED GENETIC TECHNOLOGI
Duration : Period :
Applied Genetic Technologi Technical Analysis Chart | AGTC | US03820J1007 | 4-Traders
Technical analysis trends APPLIED GENETIC TECHNOLOGI
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 8,00 $
Spread / Average Target 76%
EPS Revisions
Managers
NameTitle
Susan B. Washer President, Chief Executive Officer & Director
William A. Sullivan Chief Financial Officer
Mark S. Shearman Chief Scientific Officer & Vice President
Matthew Feinsod Chief Medical Officer
Lanita C. Scott VP-Clinical Research & Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
APPLIED GENETIC TECHNOLOGIES CORP26.39%79
GILEAD SCIENCES-1.97%89 796
VERTEX PHARMACEUTICALS3.44%38 655
REGENERON PHARMACEUTICALS-16.13%33 439
NEUROCRINE BIOSCIENCES, INC.31.87%9 196
GENMAB-6.69%9 076